EU AI Act

The FDA is developing regulatory frameworks for generative AI in medical devices, establishing precedent for how AI-driven medical technologies will be governed. This proactive stance provides critical insights for EU AI Act practitioners navigating the high-risk medical device classification and real-world compliance requirements.

• →FDA Establishing Generative AI Governance Framework for Medical Devices: EU practitioners must align with emerging FDA standards on AI validation, transparency, and post-market monitoring to ensure transatlantic compliance for medical device manufacturers.
• →Real-World Regulatory Challenges Informing AI Act Implementation: FDA's practical approach to non-deterministic AI behavior and performance validation directly informs how EU regulators will likely interpret and enforce AI Act requirements for high-risk medical applications.
• →Precedent for Risk-Based Classification of Generative AI Systems: FDA's methodology for assessing generative AI risk in medical contexts provides a template that EU regulators may adopt, affecting how practitioners classify and document AI systems under the AI Act.

Monitor FDA guidance documents on generative AI in medical devices closely and begin mapping FDA compliance requirements to EU AI Act obligations to prepare for harmonized standards.